Stephanie Allen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Stephanie Allen has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Mark David Kilby
University of Birmingham, Birmingham, UK
4 shared publications - James Castleman
Birmingham Women's Hospital Birmingham UK
3 shared publications - Lyn S. Chitty
North Thames Genomic Laboratory Hub Great Ormond Street Hospital for Children NHS Foundation Trust London UK
3 shared publications - Natalie Jane Chandler
North Thames Genomic Laboratory Hub Great Ormond Street Hospital NHS Foundation Trust London UK
3 shared publications - Amy Gerrish
West Midlands Regional Genetics Service, Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham B15 2TG, UK
2 shared publications - Chipo Mashayamombe-Wolfgarten
West Midlands Regional Genetics Service, Birmingham Women’s Hospital, Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham B15 2TG, UK
2 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Wiley in Prenatal Diagnosis
- Vol. 46 (12) , 1871-1878
Diagnostic Yield of Sequencing in Prenatal Agenesis of the Corpus Callosum in a Well‐Phenotyped International Cohort
Objective: To evaluate the incremental diagnostic yield of sequencing in a large, well‐phenotyped international cohort of fetuses with prenatally diagnosed agenesis of the corpus callosum (ACC) and to identify associated genes and variants. Methods: Retrospective multicenter cohort study of fetuses with a prenatal diagnosis of ACC undergoing sequencing after nondiagnostic chromosomal microarray. Clinical data were obtained from prenatal ultrasound and fetal MRI reports. Cases were classified as isolated ACC, ACC with additional central nervous system (CNS) abnormalities, or ACC with extracranial abnormalities. Variants were classified according to the ACMG or ACGS criteria. Results: Among 321 fetuses with ACC, a pathogenic or likely pathogenic (P/LP) variant was identified in 97 cases (30.2%). Diagnostic yield increased with phenotypic complexity: 17.3% in isolated ACC, 25.7% in ACC with additional CNS abnormalities, and 41.0% in ACC with extracranial abnormalities. MRI confirmation was available in 249 cases (77.6%) and did not alter overall diagnostic yield of genetic testing. No significant difference in yield was observed between complete ACC and other ACC types. P/LP variants were identified in 51 genes, most frequently TUBA1A . Conclusion: Sequencing provides substantial diagnostic yield in prenatally diagnosed ACC, particularly when additional CNS or extracranial anomalies are present. These findings support the use of exome or genome sequencing in the prenatal evaluation of ACC and emphasize the importance of detailed phenotyping to improve classification, interpretation and counseling.
- 25 September 2026
- Published by Wiley in Prenatal Diagnosis
- Vol. 46 (12) , 1871-1878
Open AccessDiagnostic Yield of Sequencing in Prenatal Agenesis of the Corpus Callosum in a Well‐Phenotyped International Cohort
Objective: To evaluate the incremental diagnostic yield of sequencing in a large, well‐phenotyped international cohort of fetuses with prenatally diagnosed agenesis of the corpus callosum (ACC) and to identify associated genes and variants. Methods: Retrospective multicenter cohort study of fetuses with a prenatal diagnosis of ACC undergoing sequencing after nondiagnostic chromosomal microarray. Clinical data were obtained from prenatal ultrasound and fetal MRI reports. Cases were classified as isolated ACC, ACC with additional central nervous system (CNS) abnormalities, or ACC with extracranial abnormalities. Variants were classified according to the ACMG or ACGS criteria. Results: Among 321 fetuses with ACC, a pathogenic or likely pathogenic (P/LP) variant was identified in 97 cases (30.2%). Diagnostic yield increased with phenotypic complexity: 17.3% in isolated ACC, 25.7% in ACC with additional CNS abnormalities, and 41.0% in ACC with extracranial abnormalities. MRI confirmation was available in 249 cases (77.6%) and did not alter overall diagnostic yield of genetic testing. No significant difference in yield was observed between complete ACC and other ACC types. P/LP variants were identified in 51 genes, most frequently TUBA1A . Conclusion: Sequencing provides substantial diagnostic yield in prenatally diagnosed ACC, particularly when additional CNS or extracranial anomalies are present. These findings support the use of exome or genome sequencing in the prenatal evaluation of ACC and emphasize the importance of detailed phenotyping to improve classification, interpretation and counseling.
- Open Access
- 12 December 2024
- Published by S. Karger AG in Public Health Genomics
- Vol. 28 (1) , 34-52
Evaluating the Implementation of the Rapid Prenatal Exome Sequencing Service in England
Introduction: In October 2020, a national rapid prenatal exome sequencing (pES) service was rolled out across the English National Health Service (NHS). This service is delivered by multiple clinical and two laboratory teams. While there was high level national guidance to support implementation, it was unclear how the service had been delivered in practice. This study evaluated pES service implementation across England, using the major system change (MSC) framework to explore links between implementation approaches and outcomes. Methods: We conducted a national mixed-methods multi-site study of 17 clinical genomics services, their linked fetal medicine services and two laboratories delivering the pES service. The MSC framework informed the study. Key documents, semi-structured interviews (eight national service developers, 55 staff), and surveys (n = 159 staff) were analysed using inductive and deductive thematic analysis and descriptive statistics. Findings were integrated. Results: Implementation was influenced by a range of factors including evidence of benefit, laboratory service reconfiguration, and stakeholder support. Local implementation approaches varied; seven models of service delivery were identified. Key differences between models included leadership, staffing, and multidisciplinary team approaches. Local staff factors (e.g., time, capacity, attitudes), pES service factors (e.g., communication/collaboration, logistics), and organisational factors (e.g., infrastructure and previous experience) influenced implementation. Conclusion: We have identified multiple barriers and facilitators that are associated with implementing a major change to genomic services in a complex national healthcare system. This study highlights which models of pES may work in practice and why. Findings will inform future development of the pES service.
- 12 December 2024
- Published by S. Karger AG in Public Health Genomics
- Vol. 28 (1) , 34-52
Open AccessEvaluating the Implementation of the Rapid Prenatal Exome Sequencing Service in England
Introduction: In October 2020, a national rapid prenatal exome sequencing (pES) service was rolled out across the English National Health Service (NHS). This service is delivered by multiple clinical and two laboratory teams. While there was high level national guidance to support implementation, it was unclear how the service had been delivered in practice. This study evaluated pES service implementation across England, using the major system change (MSC) framework to explore links between implementation approaches and outcomes. Methods: We conducted a national mixed-methods multi-site study of 17 clinical genomics services, their linked fetal medicine services and two laboratories delivering the pES service. The MSC framework informed the study. Key documents, semi-structured interviews (eight national service developers, 55 staff), and surveys (n = 159 staff) were analysed using inductive and deductive thematic analysis and descriptive statistics. Findings were integrated. Results: Implementation was influenced by a range of factors including evidence of benefit, laboratory service reconfiguration, and stakeholder support. Local implementation approaches varied; seven models of service delivery were identified. Key differences between models included leadership, staffing, and multidisciplinary team approaches. Local staff factors (e.g., time, capacity, attitudes), pES service factors (e.g., communication/collaboration, logistics), and organisational factors (e.g., infrastructure and previous experience) influenced implementation. Conclusion: We have identified multiple barriers and facilitators that are associated with implementing a major change to genomic services in a complex national healthcare system. This study highlights which models of pES may work in practice and why. Findings will inform future development of the pES service.
- 3 September 2024
- Published by Elsevier in Best Practice & Research Clinical Obstetrics & Gynaecology
- Vol. 97, 102544
Chapter 2: Non-invasive prenatal diagnosis
- 3 September 2024
- Published by Elsevier in Best Practice & Research Clinical Obstetrics & Gynaecology
- Vol. 97, 102544
Chapter 2: Non-invasive prenatal diagnosis
- Open Access
Genetic Diagnosis of Retinoblastoma Using Aqueous Humour—Findings from an Extended Cohort
The identification of somatic RB1 variation is crucial to confirm the heritability of retinoblastoma. We and others have previously shown that, when tumour DNA is unavailable, cell-free DNA (cfDNA) derived from aqueous humour (AH) can be used to identify somatic RB1 pathogenic variation. Here we report RB1 pathogenic variant detection, as well as cfDNA concentration in an extended cohort of 75 AH samples from 68 patients. We show cfDNA concentration is highly variable and significantly correlated with the collection point of the AH. Cell-free DNA concentrations above 5 pg/µL enabled the detection of 93% of known or expected RB1 pathogenic variants. In AH samples collected during intravitreal chemotherapy treatment (Tx), the yield of cfDNA above 5 pg/µL and subsequent variant detection was low (≤46%). However, AH collected by an anterior chamber tap after one to three cycles of primary chemotherapy (Dx1+) enabled the detection of 75% of expected pathogenic variants. Further limiting our analysis to Dx1+ samples taken after ≤2 cycles (Dx ≤ 2) provided measurable levels of cfDNA in all cases, and a subsequent variant detection rate of 95%. Early AH sampling is therefore likely to be important in maximising cfDNA concentration and the subsequent detection of somatic RB1 pathogenic variants in retinoblastoma patients undergoing conservative treatment.
Open AccessGenetic Diagnosis of Retinoblastoma Using Aqueous Humour—Findings from an Extended Cohort
The identification of somatic RB1 variation is crucial to confirm the heritability of retinoblastoma. We and others have previously shown that, when tumour DNA is unavailable, cell-free DNA (cfDNA) derived from aqueous humour (AH) can be used to identify somatic RB1 pathogenic variation. Here we report RB1 pathogenic variant detection, as well as cfDNA concentration in an extended cohort of 75 AH samples from 68 patients. We show cfDNA concentration is highly variable and significantly correlated with the collection point of the AH. Cell-free DNA concentrations above 5 pg/µL enabled the detection of 93% of known or expected RB1 pathogenic variants. In AH samples collected during intravitreal chemotherapy treatment (Tx), the yield of cfDNA above 5 pg/µL and subsequent variant detection was low (≤46%). However, AH collected by an anterior chamber tap after one to three cycles of primary chemotherapy (Dx1+) enabled the detection of 75% of expected pathogenic variants. Further limiting our analysis to Dx1+ samples taken after ≤2 cycles (Dx ≤ 2) provided measurable levels of cfDNA in all cases, and a subsequent variant detection rate of 95%. Early AH sampling is therefore likely to be important in maximising cfDNA concentration and the subsequent detection of somatic RB1 pathogenic variants in retinoblastoma patients undergoing conservative treatment.
- 8 December 2023
- Published by Wiley in Prenatal Diagnosis
- Vol. 44 (4) , 432-442
Diagnosis of inborn errors of metabolism through prenatal exome sequencing with targeted analysis for fetal structural anomalies
Objectives: The value of prenatal exome sequencing (pES) for fetuses with structural anomalies is widely reported. In England, testing is conducted through trio exome sequencing and analysis of a gene panel. Over a 30‐month period testing of 921 pregnancies resulted in a genetic diagnosis in 32.8% of cases (302/921). Here we review cases diagnosed with an inborn error of metabolism.Methods: Diagnoses of inborn errors of metabolism (IEM) were classified according to the ICIMD classification system. Genetic diagnoses were assessed against Human Phenotype Ontology terms, gestation of scan findings and literature evidence.Results: 35/302 diagnoses (11.6%) represented IEM. Almost half affected metabolism of complex macromolecules and organelles (n = 16), including congenital disorders of glycosylation (n = 8), peroxisome biogenesis disorders (n = 4), and lysosomal storage disorders (n = 4). There were eight disorders of lipid metabolism and transport, the majority being genes in the cholesterol biosynthesis pathway, eight disorders of intermediary metabolism, of which seven were defects in “energy” processes, and two diagnoses of alkaline phosphatase deficiency.Conclusions: Review of pES diagnoses and ultrasound scan findings is key to understanding genotype‐phenotype correlations. IEM are genetically heterogeneous and may present with variable scan findings, which makes an individual diagnosis difficult to suspect. Diagnosis during pregnancy is particularly important for many IEM with respect to prognosis and early neonatal management.
- 8 December 2023
- Published by Wiley in Prenatal Diagnosis
- Vol. 44 (4) , 432-442
Diagnosis of inborn errors of metabolism through prenatal exome sequencing with targeted analysis for fetal structural anomalies
Objectives: The value of prenatal exome sequencing (pES) for fetuses with structural anomalies is widely reported. In England, testing is conducted through trio exome sequencing and analysis of a gene panel. Over a 30‐month period testing of 921 pregnancies resulted in a genetic diagnosis in 32.8% of cases (302/921). Here we review cases diagnosed with an inborn error of metabolism.Methods: Diagnoses of inborn errors of metabolism (IEM) were classified according to the ICIMD classification system. Genetic diagnoses were assessed against Human Phenotype Ontology terms, gestation of scan findings and literature evidence.Results: 35/302 diagnoses (11.6%) represented IEM. Almost half affected metabolism of complex macromolecules and organelles (n = 16), including congenital disorders of glycosylation (n = 8), peroxisome biogenesis disorders (n = 4), and lysosomal storage disorders (n = 4). There were eight disorders of lipid metabolism and transport, the majority being genes in the cholesterol biosynthesis pathway, eight disorders of intermediary metabolism, of which seven were defects in “energy” processes, and two diagnoses of alkaline phosphatase deficiency.Conclusions: Review of pES diagnoses and ultrasound scan findings is key to understanding genotype‐phenotype correlations. IEM are genetically heterogeneous and may present with variable scan findings, which makes an individual diagnosis difficult to suspect. Diagnosis during pregnancy is particularly important for many IEM with respect to prognosis and early neonatal management.
- Open Access
- 6 December 2023
- Published by Wiley in Prenatal Diagnosis
- Vol. 44 (4) , 422-431
Monogenic conditions and central nervous system anomalies: A prospective study, systematic review and meta‐analysis
Objectives: Determine the incremental diagnostic yield of prenatal exome sequencing (pES) over chromosome microarray (CMA) or G‐banding karyotype in fetuses with central nervous system (CNS) abnormalities.Methods: Data were collected via electronic searches from January 2010 to April 2022 in MEDLINE, Cochrane, Web of Science and EMBASE. The NHS England prenatal exome cohort was also included. Incremental yield was calculated as a pooled value using a random‐effects model.Results: Thirty studies were included (n = 1583 cases). The incremental yield with pES for any CNS anomaly was 32% [95%CI 27%–36%; I2 = 72%]. Subgroup analysis revealed apparent incremental yields in; (a) isolated CNS anomalies; 27% [95%CI 19%–34%; I2 = 74%]; (b) single CNS anomaly; 16% [95% CI 10%–23%; I2 = 41%]; (c) more than one CNS anomaly; 31% [95% Cl 21%–40%; I2 = 56%]; and (d) the anatomical subtype with the most optimal yield was Type 1 malformation of cortical development, related to abnormal cell proliferation or apoptosis, incorporating microcephalies, megalencephalies and dysplasia; 40% (22%–57%; I2 = 68%). The commonest syndromes in isolated cases were Lissencephaly 3 and X‐linked hydrocephalus.Conclusions: Prenatal exome sequencing provides a high incremental diagnostic yield in fetuses with CNS abnormalities with optimal yields in cases with multiple CNS anomalies, particularly those affecting the midline, posterior fossa and cortex.
- 6 December 2023
- Published by Wiley in Prenatal Diagnosis
- Vol. 44 (4) , 422-431
Open AccessMonogenic conditions and central nervous system anomalies: A prospective study, systematic review and meta‐analysis
Objectives: Determine the incremental diagnostic yield of prenatal exome sequencing (pES) over chromosome microarray (CMA) or G‐banding karyotype in fetuses with central nervous system (CNS) abnormalities.Methods: Data were collected via electronic searches from January 2010 to April 2022 in MEDLINE, Cochrane, Web of Science and EMBASE. The NHS England prenatal exome cohort was also included. Incremental yield was calculated as a pooled value using a random‐effects model.Results: Thirty studies were included (n = 1583 cases). The incremental yield with pES for any CNS anomaly was 32% [95%CI 27%–36%; I2 = 72%]. Subgroup analysis revealed apparent incremental yields in; (a) isolated CNS anomalies; 27% [95%CI 19%–34%; I2 = 74%]; (b) single CNS anomaly; 16% [95% CI 10%–23%; I2 = 41%]; (c) more than one CNS anomaly; 31% [95% Cl 21%–40%; I2 = 56%]; and (d) the anatomical subtype with the most optimal yield was Type 1 malformation of cortical development, related to abnormal cell proliferation or apoptosis, incorporating microcephalies, megalencephalies and dysplasia; 40% (22%–57%; I2 = 68%). The commonest syndromes in isolated cases were Lissencephaly 3 and X‐linked hydrocephalus.Conclusions: Prenatal exome sequencing provides a high incremental diagnostic yield in fetuses with CNS abnormalities with optimal yields in cases with multiple CNS anomalies, particularly those affecting the midline, posterior fossa and cortex.
- 21 October 2022
- Published by Wiley in Prenatal Diagnosis
- Vol. 42 (12) , 1481-1483
Prenatal diagnosis of PERCHING syndrome caused by homozygous loss of function variant in the KLHL7 gene
Aims: A couple were referred for prenatal genetic testing at 31 weeks' gestation due to the presence of mild polyhydramnios and multiple central nervous system (CNS) abnormalities, including borderline ventriculomegaly, possible delayed sulcation, an enlarged cisterna magna and a small area of calcification around the posterior horns. Testing was initiated to identify any underlying genetic cause.Materials and Methods: Rapid trio exome sequencing (ES) was performed on DNA extracted from parental blood samples and amniotic fluid.Results: A pathogenic homozygous nonsense variant in KLHL7 (NM_001031710.2) associated with PERCHING syndrome (#617055) was identified.Conclusion: Whilst there are detailed descriptions of the many postnatal phenotypes seen in these patients, there are few reports of features identified during pregnancy. This report is the first published prenatal diagnosis of PERCHING syndrome and provides further information on the associated fetal phenotypes.
- 21 October 2022
- Published by Wiley in Prenatal Diagnosis
- Vol. 42 (12) , 1481-1483
Prenatal diagnosis of PERCHING syndrome caused by homozygous loss of function variant in the KLHL7 gene
Aims: A couple were referred for prenatal genetic testing at 31 weeks' gestation due to the presence of mild polyhydramnios and multiple central nervous system (CNS) abnormalities, including borderline ventriculomegaly, possible delayed sulcation, an enlarged cisterna magna and a small area of calcification around the posterior horns. Testing was initiated to identify any underlying genetic cause.Materials and Methods: Rapid trio exome sequencing (ES) was performed on DNA extracted from parental blood samples and amniotic fluid.Results: A pathogenic homozygous nonsense variant in KLHL7 (NM_001031710.2) associated with PERCHING syndrome (#617055) was identified.Conclusion: Whilst there are detailed descriptions of the many postnatal phenotypes seen in these patients, there are few reports of features identified during pregnancy. This report is the first published prenatal diagnosis of PERCHING syndrome and provides further information on the associated fetal phenotypes.
- Open Access
Next Generation Sequencing after Invasive Prenatal Testing in Fetuses with Congenital Malformations: Prenatal or Neonatal Investigation
Congenital malformations diagnosed by ultrasound screening complicate 3–5% of pregnancies and many of these have an underlying genetic cause. Approximately 40% of prenatally diagnosed fetal malformations are associated with aneuploidy or copy number variants, detected by conventional karyotyping, QF-PCR and microarray techniques, however monogenic disorders are not diagnosed by these tests. Next generation sequencing as a secondary prenatal genetic test offers additional diagnostic yield for congenital abnormalities deemed to be potentially associated with an underlying genetic aetiology, as demonstrated by two large cohorts: the ‘Prenatal assessment of genomes and exomes’ (PAGE) study and ‘Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study’ performed at Columbia University in the US. These were large and prospective studies but relatively ‘unselected’ congenital malformations, with little Clinical Genetics input to the pre-test selection process. This review focuses on the incremental yield of next generation sequencing in single system congenital malformations, using evidence from the PAGE, Columbia and subsequent cohorts, with particularly high yields in those fetuses with cardiac and neurological anomalies, large nuchal translucency and non-immune fetal hydrops (of unknown aetiology). The total additional yield gained by exome sequencing in congenital heart disease was 12.7%, for neurological malformations 13.8%, 13.1% in increased nuchal translucency and 29% in non-immune fetal hydrops. This demonstrates significant incremental yield with exome sequencing in single-system anomalies and supports next generation sequencing as a secondary genetic test in routine clinical care of fetuses with congenital abnormalities.
Open AccessNext Generation Sequencing after Invasive Prenatal Testing in Fetuses with Congenital Malformations: Prenatal or Neonatal Investigation
Congenital malformations diagnosed by ultrasound screening complicate 3–5% of pregnancies and many of these have an underlying genetic cause. Approximately 40% of prenatally diagnosed fetal malformations are associated with aneuploidy or copy number variants, detected by conventional karyotyping, QF-PCR and microarray techniques, however monogenic disorders are not diagnosed by these tests. Next generation sequencing as a secondary prenatal genetic test offers additional diagnostic yield for congenital abnormalities deemed to be potentially associated with an underlying genetic aetiology, as demonstrated by two large cohorts: the ‘Prenatal assessment of genomes and exomes’ (PAGE) study and ‘Whole-exome sequencing in the evaluation of fetal structural anomalies: a prospective cohort study’ performed at Columbia University in the US. These were large and prospective studies but relatively ‘unselected’ congenital malformations, with little Clinical Genetics input to the pre-test selection process. This review focuses on the incremental yield of next generation sequencing in single system congenital malformations, using evidence from the PAGE, Columbia and subsequent cohorts, with particularly high yields in those fetuses with cardiac and neurological anomalies, large nuchal translucency and non-immune fetal hydrops (of unknown aetiology). The total additional yield gained by exome sequencing in congenital heart disease was 12.7%, for neurological malformations 13.8%, 13.1% in increased nuchal translucency and 29% in non-immune fetal hydrops. This demonstrates significant incremental yield with exome sequencing in single-system anomalies and supports next generation sequencing as a secondary genetic test in routine clinical care of fetuses with congenital abnormalities.
- 15 May 2021
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 73
Current clinical practice of prenatal dexamethasone treatment in at risk pregnancies for classic 21‑hydroxylase deficiency in Europe
Background Prenatal dexamethasone treatment (Pdex) has been used since the 1980s to prevent virilization in female offspring suspected to have congenital adrenal hyperplasia (CAH). However, due to lack of strong evidence for its best practice as well as limited data regarding longterm adverse effects, use of dex is highly controversial. This study reveals the current medical practice regarding Pdex in female fetuses at risk of CAH due to 21hydroxylase deficiency (21OHD) in Europe. Methods A questionnaire was designed and distributed using Microsoft Forms, including 17 questions collecting quantitative and qualitative data. Thirty-six medical centres from 14 European countries responded and 28 out of 36 centres were reference centres of the European Reference Network on Rare Endocrine Conditions, EndoERN. Results 36% (13/36) of the surveyed centres are currently providing Pdex. The treatment is initiated by different specialties i.e. pediatricians, obstetricians/gynecologists or geneticists. Regarding the starting point of Pdex, 15% of centres stated to initiate therapy as early as pregnancy is confirmed, 23% at 4 to 5 wpc, 31% at 6 wpc, and the rest at 7 wpc at the latest. A dose of 20 µg/kg/d is used and dose distribution among the centres varies between once to thrice daily. Prenatal diagnostics are conducted at 72% (26/36) of centres, which however mainly includes chorionic villous sampling ± genotyping of the sexdetermining region Y from maternal blood (SRYtyping) or amniocentesis and CYP21A2 genotyping. Noninvasive genetic testing from maternal blood is currently offered by one centre. The total number of pregnant women who received Pdex during the first trimester of pregnancy varied from 3 to 44 per centre (median = 10, total number of treated cases n = 197), while 0 to 13 cases (median = 5, total number of treated cases n = 70) were treated for the entire gestational period. A mean of 1.6 cases are treated at each centre per year. Registries for longterm followup are only available at 46% of the centres that are using Pdex. National registries are only available in 2 of the 14 corresponding countries. Conclusion This study reveals a high international variability and discrepancy on the use of Pdex across Europe. It highlights the importance of a European cooperation initiative for a joint international prospective trial to establish evidencebased guidelines on prenatal diagnostics, treatment and followup of pregnancies at risk for CAH. Evaluation of outcome and longterm health of already treated cases across Europe is highly recommended.
- 15 May 2021
- Published by Bioscientifica in Endocrine Abstracts
- Vol. 73
Current clinical practice of prenatal dexamethasone treatment in at risk pregnancies for classic 21‑hydroxylase deficiency in Europe
Background Prenatal dexamethasone treatment (Pdex) has been used since the 1980s to prevent virilization in female offspring suspected to have congenital adrenal hyperplasia (CAH). However, due to lack of strong evidence for its best practice as well as limited data regarding longterm adverse effects, use of dex is highly controversial. This study reveals the current medical practice regarding Pdex in female fetuses at risk of CAH due to 21hydroxylase deficiency (21OHD) in Europe. Methods A questionnaire was designed and distributed using Microsoft Forms, including 17 questions collecting quantitative and qualitative data. Thirty-six medical centres from 14 European countries responded and 28 out of 36 centres were reference centres of the European Reference Network on Rare Endocrine Conditions, EndoERN. Results 36% (13/36) of the surveyed centres are currently providing Pdex. The treatment is initiated by different specialties i.e. pediatricians, obstetricians/gynecologists or geneticists. Regarding the starting point of Pdex, 15% of centres stated to initiate therapy as early as pregnancy is confirmed, 23% at 4 to 5 wpc, 31% at 6 wpc, and the rest at 7 wpc at the latest. A dose of 20 µg/kg/d is used and dose distribution among the centres varies between once to thrice daily. Prenatal diagnostics are conducted at 72% (26/36) of centres, which however mainly includes chorionic villous sampling ± genotyping of the sexdetermining region Y from maternal blood (SRYtyping) or amniocentesis and CYP21A2 genotyping. Noninvasive genetic testing from maternal blood is currently offered by one centre. The total number of pregnant women who received Pdex during the first trimester of pregnancy varied from 3 to 44 per centre (median = 10, total number of treated cases n = 197), while 0 to 13 cases (median = 5, total number of treated cases n = 70) were treated for the entire gestational period. A mean of 1.6 cases are treated at each centre per year. Registries for longterm followup are only available at 46% of the centres that are using Pdex. National registries are only available in 2 of the 14 corresponding countries. Conclusion This study reveals a high international variability and discrepancy on the use of Pdex across Europe. It highlights the importance of a European cooperation initiative for a joint international prospective trial to establish evidencebased guidelines on prenatal diagnostics, treatment and followup of pregnancies at risk for CAH. Evaluation of outcome and longterm health of already treated cases across Europe is highly recommended.